These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 8622113)
1. Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. Jones RN J Chemother; 1995 Jun; 7 Suppl 2():7-16. PubMed ID: 8622113 [TBL] [Abstract][Full Text] [Related]
2. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. Miller GH; Sabatelli FJ; Naples L; Hare RS; Shaw KJ J Chemother; 1995 Jun; 7 Suppl 2():31-44. PubMed ID: 8622109 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections. Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627 [TBL] [Abstract][Full Text] [Related]
4. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031 [TBL] [Abstract][Full Text] [Related]
5. The most frequently occurring aminoglycoside resistance mechanisms--combined results of surveys in eight regions of the world. The Aminoglycoside Resistance Study Groups. J Chemother; 1995 Jun; 7 Suppl 2():17-30. PubMed ID: 8622108 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Fritsche TR; Stilwell MG; Jones RN Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551 [TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Sader HS; Jones RN; Dowzicky MJ; Fritsche TR Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565 [TBL] [Abstract][Full Text] [Related]
8. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Rhomberg PR; Jones RN Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243 [TBL] [Abstract][Full Text] [Related]
9. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Fritsche TR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139 [TBL] [Abstract][Full Text] [Related]
10. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005]. Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265 [TBL] [Abstract][Full Text] [Related]
11. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Gales AC; Jones RN; Sader HS Clin Microbiol Infect; 2006 Apr; 12(4):315-21. PubMed ID: 16524407 [TBL] [Abstract][Full Text] [Related]
12. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511 [TBL] [Abstract][Full Text] [Related]
14. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents. Bell JM; Turnidge JD; Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610 [TBL] [Abstract][Full Text] [Related]
15. Antibiotic use in neonatal sepsis. Yurdakök M Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468 [TBL] [Abstract][Full Text] [Related]
16. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569 [TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of nosocomial isolates against a new aminoglycoside isepamicin. Kapil A; Bali R; Das BK Indian J Med Res; 2001 Feb; 113():60-2. PubMed ID: 21910285 [TBL] [Abstract][Full Text] [Related]